Literature DB >> 17911581

Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites.

Nathalie Chaput1, Guillaume Darrasse-Jèze, Anne-Sophie Bergot, Corinne Cordier, Stacie Ngo-Abdalla, David Klatzmann, Orly Azogui.   

Abstract

Natural regulatory T cells (Tregs) are present in high frequencies among tumor-infiltrating lymphocytes and in draining lymph nodes, supposedly facilitating tumor development. To investigate their role in controlling local immune responses, we analyzed intratumoral T cell accumulation and function in the presence or absence of Tregs. Tumors that grew in normal BALB/c mice injected with the 4T1 tumor cell line were highly infiltrated by Tregs, CD4 and CD8 cells, all having unique characteristics. Most infiltrating Tregs expressed low levels of CD25Rs and Foxp3. They did not proliferate even in the presence of IL-2 but maintained a strong suppressor activity. CD4 T cells were profoundly anergic and CD8 T cell proliferation and cytotoxicity were severely impaired. Depletion of Tregs modified the characteristics of tumor infiltrates. Tumors were initially invaded by activated CD4(+)CD25(-) T cells, which produced IL-2 and IFN-gamma. This was followed by the recruitment of highly cytotoxic CD8(+) T cells at tumor sites leading to tumor rejection. The beneficial effect of Treg depletion in tumor regression was abrogated when CD4 helper cells were also depleted. These findings indicate that the massive infiltration of tumors by Tregs prevents the development of a successful helper response. The Tregs in our model prevent Th cell activation and subsequent development of efficient CD8 T cell activity required for the control of tumor growth.

Entities:  

Mesh:

Year:  2007        PMID: 17911581     DOI: 10.4049/jimmunol.179.8.4969

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.

Authors:  Qifeng Zhou; Haiyan Xiao; Yanjun Liu; Yibing Peng; Yuan Hong; Hideo Yagita; Phillip Chandler; David H Munn; Andrew Mellor; Ning Fu; Yukai He
Journal:  J Immunol       Date:  2010-10-06       Impact factor: 5.422

2.  Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells.

Authors:  Xin Chen; Ryoko Hamano; Jeffrey J Subleski; Arthur A Hurwitz; O M Zack Howard; Joost J Oppenheim
Journal:  J Immunol       Date:  2010-06-04       Impact factor: 5.422

3.  Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent.

Authors:  Nafiseh Pakravan; Seyed Mahmoud Hashemi; Zuhair Mohammad Hassan
Journal:  Cell Stress Chaperones       Date:  2010-08-22       Impact factor: 3.667

4.  TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies.

Authors:  Tristan Courau; Djamel Nehar-Belaid; Laura Florez; Béatrice Levacher; Thomas Vazquez; Faustine Brimaud; Bertrand Bellier; David Klatzmann
Journal:  JCI Insight       Date:  2016-06-16

5.  Primary 4T1 tumor resection provides critical "window of opportunity" for immunotherapy.

Authors:  Anahit Ghochikyan; Arpine Davtyan; Armine Hovakimyan; Hayk Davtyan; Anna Poghosyan; Alexander Bagaev; Ravshan I Ataullakhanov; Edward L Nelson; Michael G Agadjanyan
Journal:  Clin Exp Metastasis       Date:  2013-10-06       Impact factor: 5.150

6.  Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts.

Authors:  Christian H Poehlein; Daniel P Haley; Edwin B Walker; Bernard A Fox
Journal:  Eur J Immunol       Date:  2009-11       Impact factor: 5.532

7.  Antigen quality determines the efficiency of antitumor immune responses generated in the absence of regulatory T cells.

Authors:  A-S Bergot; A Durgeau; B Levacher; B M Colombo; J L Cohen; D Klatzmann
Journal:  Cancer Gene Ther       Date:  2010-05-14       Impact factor: 5.987

8.  IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients.

Authors:  Geok Choo Sim; Natalia Martin-Orozco; Lei Jin; Yan Yang; Sheng Wu; Edwina Washington; Deborah Sanders; Carol Lacey; Yijun Wang; Luis Vence; Patrick Hwu; Laszlo Radvanyi
Journal:  J Clin Invest       Date:  2014-01       Impact factor: 14.808

9.  Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4+ T cells.

Authors:  Arnaud Pommier; Alexandra Audemard; Aurélie Durand; Renée Lengagne; Arnaud Delpoux; Bruno Martin; Laetitia Douguet; Armelle Le Campion; Masashi Kato; Marie-Françoise Avril; Cédric Auffray; Bruno Lucas; Armelle Prévost-Blondel
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-22       Impact factor: 11.205

10.  Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice.

Authors:  Guillaume Darrasse-Jèze; Anne-Sophie Bergot; Aurélie Durgeau; Fabienne Billiard; Benoît L Salomon; José L Cohen; Bertrand Bellier; Katrina Podsypanina; David Klatzmann
Journal:  J Clin Invest       Date:  2009-08-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.